• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Best Managed Accounts
  • Forex Robots
  • Forex Brokers
  • Forex Signals
  • Social Trading Platforms

Forex Traders Guide

The Ultimate Forex Knowledge Base

  • Robots
  • Start Guide
  • Glossary
  • Basics
    • Currency Pairs
    • Charts
    • Candlesticks
    • Trading Tips
  • Strategies
    • Technical Analysis
    • Fundamental Analysis
    • Day Trading
    • Scalping
    • Swing Trading
    • Trend Following
  • News
  • Reviews
    • Forex Robots
    • Forex Brokers
  • Mustreads
  • Crypto Trading

Theseus Pharmaceuticals Terminates Development of THE-630

July 15, 2023 by Forex Winner Leave a Comment

Shares of Theseus Pharmaceuticals took a significant hit on Friday following the company’s announcement that it would be discontinuing the development of THE-630 for patients with gastrointestinal stromal tumors.

The decision to terminate development came after the company discovered two dose-limiting toxicities associated with hand-foot skin reaction. As a result, Theseus Pharmaceuticals will now prioritize the development of THE-349 for EGFR mutant non-small cell lung cancer. The company plans to submit an investigational new drug application for THE-349 in the fourth quarter.

Best Forex Robots ›

Compare leading trading systems on the market

At 3:22 p.m. EDT, Theseus Pharmaceuticals’ stock was trading at $2.65 per share, marking a staggering decrease of 72.1%. The volume of shares being traded at that time exceeded the stock’s 65-day average volume of 214,407 shares, reaching 9.4 million shares.

The stock opened at $3.20 per share on Friday, showing a significant drop from its previous closing price of $9.52 on Thursday. During the trading session, the stock hit a 52-week low of $2.64 per share.

In addition to the drop in share price, financial firms HC Wainwright & Co. and Cantor Fitzgerald have revised their price targets for Theseus Pharmaceuticals. HC Wainwright & Co. has lowered its price target to $9 per share from $22, while Cantor Fitzgerald has reduced its price target to $7 per share from $23.

These developments reflect the current challenges faced by Theseus Pharmaceuticals in their pursuit of effective treatments for cancer patients.

Best Forex Robots ›

Compare leading trading systems on the market

Filed Under: Forex News Tagged With: Drug Development, Gastrointestinal Stromal Tumors, stock market, THE-630, Theseus Pharmaceuticals

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Best Forex Robots

  1. Techberry 8.7
  2. Happy Forex 8.0
  3. Forex Fury 7.7
  4. Promax Gold EA 6.8
  5. Gump EA 6.4

Best Forex Brokers

  1. Techberry 8.7
  2. XM 8.2
  3. eToro 8.1
  4. Pepperstone 8.1
  5. IG 8.0

Latest News

High Blood Pressure in Seniors: A Balancing Act

September 30, 2023

Auto Strikes Cause Stock Market Struggles

September 29, 2023

Supreme Court to Review Conflicting Laws on Social Media Content Moderation

September 29, 2023

Footer

Forex Broker Reviews

NinjaTrader Review

February 17, 2020 By Forex Winner

TradeStation

TradeStation Review

July 1, 2019 By Forex Winner

FXCM

FXCM Review

November 13, 2019 By Forex Winner

Forex Robot Reviews

Earn2Trade Review

August 20, 2023 By Andre

FundedNext Review

August 16, 2023 By Andre

Topstep Forex Review

August 14, 2023 By Andre

EMAIL NEWSLETTER

Sign up to receive exclusive forex trading guides and insights from our team of experts!

Copyright © 2023 · Forex Traders Guide · About Us · Contact Us
Privacy Policy · Risk Disclosure